Leon O. Moulder Jr., who serves as both Chief Executive Officer and Chairman of Zenas BioPharma, Inc. (NASDAQ:ZBIO), recently executed an insider purchase, acquiring 60,000 shares of the company’s common stock on May 18, 2026. According to a filing with the SEC, these transactions amounted to $1,012,799.
This substantial acquisition by executive leadership comes at a time when the stock has seen an approximate decline of 12% over the preceding week. Despite this short-term dip, the shares maintain a considerable appreciation of about 54% when compared to their value one year prior.
Details of Executive Holdings and Transactions
Mr. Moulder acquired these shares across a price range spanning from $16.59 to $16.97 per share, resulting in a weighted average purchase price of $16.88. Following the completion of this buying activity, Mr. Moulder's direct holdings of Zenas BioPharma common stock increased to 423,155 shares.
Furthermore, his beneficial ownership includes indirect stakes through other entities. Specifically, he holds an indirect beneficial interest of 96,928 shares via the Leon O. Moulder, Jr. Revocable Trust, where he acts as a Trustee. Additionally, through Tellus BioVentures LLC, where he is the Managing Member, his indirect ownership totals 1,786,039 shares. It should be noted that Mr. Moulder explicitly disclaims beneficial ownership of these indirectly held securities unless there is an explicit pecuniary interest.
From an analytical perspective, one source suggests that Zenas BioPharma's stock may appear slightly undervalued at its current trading levels, citing analyst price targets ranging broadly from $22 to $55.
Corporate Developments and Pipeline Progress
In terms of corporate development, Zenas BioPharma has progressed with several key initiatives. The company initiated a Phase 1 clinical trial for ZB021, an oral IL-17AA/AF inhibitor. This drug candidate is aimed at treating various autoimmune diseases. This specific trial will be conducted in collaboration with InnoCare Pharma within China and its primary objective will be to assess the safety profile and tolerability of the medication among healthy volunteers.
On the financial front, Zenas BioPharma completed capital-raising efforts by pricing $200 million worth of convertible senior notes and selling shares valued at $100 million. The newly issued notes carry an interest rate of 2.50% and are scheduled to mature in 2032. These funds were raised through underwritten public offerings, which included provisions allowing underwriters the option to purchase supplementary securities to cover any over-allotments.
The company's ongoing efforts are further supported by positive analyst activity. Guggenheim recently elevated its price target for Zenas BioPharma to $55 and maintained a